The Baltic States with its appropriate population size, sufficient infrastructure, and experienced and motivated investigators, make it an attractive choice for a clinical trial.
In this article, Doatas Grina, Indre Tutlyte and Auudius Sveikata, PhD, that ran in the February 2013 issue of Applied Clinical Trials, presents a persuasive case for the area’s present desirability as well as a history of steady growth in the past that indicates the Baltic clinical research market is poised to grow. Already it has proven rich in clinical research potential. Consider:
- The Baltic States approve around 80 new clinical trial applications per country each year.
- The biggest part of clinical trials performed are within the therapeutic areas of oncology, neurology/psychiatry, and endocrinology.
- Nearly 70% of the studies performed are Phase III trials.
- States legislation is harmonized and the regulatory process is similar to other EU countries.
- The timelines are attractive—the approval process takes approximately 60 days.
- The region has an appropriate population size to populate large trials.
- Its infrastructure is sufficient and their investigators are experienced and motivated.
- A considerably large pool of treatment-naïve subjects is available, similar to most of the Central and Eastern European counties. Read More